Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
FAIL · Does not pass the screen
14.60 USD
At the last full screen 2026-09-02
Screened 2026-09-02 · the tape above runs as of 19:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Summit Therapeutics Inc holds its Markup at $14.60. The statistical read favours the sellers, held for 3 days.
As held on the ledger · 2026-09-02
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 3 days
Price at the screen
$14.60
Valuation
N/A trailing · -12.20 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-1.24
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.78%
Below 33%
Interest-bearing debt is just 2.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
64.99%
Below 33%
Interest-bearing cash and securities are 65.0% of assets, above the one-third limit.
Fail
Receivables
29.99%
Below 49%
Money owed to the company is 30.0% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-02 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +128% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech dreams rarely survive first contact
Picture a drug still in trials that needs to clear regulators, win doctors and then scale across hospitals before any cash lands. Summit is that story today, with ivonescimab its single bet and no profits yet to show for the effort. The numbers underline the gap: forward earnings sit at minus 11.7 times, margins at zero and return on equity at minus 271 percent.
Analysts see upside and the ethical screen clears, yet the opportunity rating stays at none. A narrow moat plus heavy cash burn means any delay or rival advance could wipe out the apparent discount to fair value. The market has already priced in hope; execution risk sits elsewhere.
Even a clean trial result leaves years of spending and competition before real returns appear. Peak losses can persist long after the share price has run. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SMMT trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-13Markup · changed$14.60+8.6%Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28.
2026-08-13Markdown · changed$13.44-4.1%Entry 4
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28.
2026-07-18Distribution$14.01+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28.
2026-07-03Distribution$14.01+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$14.01Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
